[go: up one dir, main page]

WO1997035538A3 - Convertase du facteur alpha de necrose tumorale - Google Patents

Convertase du facteur alpha de necrose tumorale Download PDF

Info

Publication number
WO1997035538A3
WO1997035538A3 PCT/EP1997/001497 EP9701497W WO9735538A3 WO 1997035538 A3 WO1997035538 A3 WO 1997035538A3 EP 9701497 W EP9701497 W EP 9701497W WO 9735538 A3 WO9735538 A3 WO 9735538A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα
con
necrosis factor
tumor necrosis
factor alpha
Prior art date
Application number
PCT/EP1997/001497
Other languages
English (en)
Other versions
WO1997035538A2 (fr
Inventor
Gerard M Mcgeehan
James David Becherer
Marcia L Moss
Frank J Schoenen
Warren J Rocque
Wen-Ji Chen
John R Didsbury
Shiow-Lian Catherine Jin
Original Assignee
Glaxo Group Ltd
Gerard M Mcgeehan
James David Becherer
Marcia L Moss
Frank J Schoenen
Warren J Rocque
Chen Wen Ji
John R Didsbury
Jin Shiow Lian Catherine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Gerard M Mcgeehan, James David Becherer, Marcia L Moss, Frank J Schoenen, Warren J Rocque, Chen Wen Ji, John R Didsbury, Jin Shiow Lian Catherine filed Critical Glaxo Group Ltd
Priority to AU22913/97A priority Critical patent/AU2291397A/en
Priority to EP97915426A priority patent/EP0900272A2/fr
Priority to JP9534033A priority patent/JP2000507943A/ja
Publication of WO1997035538A2 publication Critical patent/WO1997035538A2/fr
Publication of WO1997035538A3 publication Critical patent/WO1997035538A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention porte sur le facteur alpha de nécrose tumorale (TNFα) et plus particulièrement sur l'enzyme TNFα-convertase (TNFα-con) assurant la conversion protéolytique du précurseur du TNFα en TNFα à maturité. L'invention porte sur des séquences d'ADN codant pour la TNFα-con de mammifère et ses équivalents fonctionnels, sur les vecteurs d'expression de recombinaison comprenant lesdites séquences d'ADN, sur des lignées de cellules hôtes comprenant lesdits vecteurs d'expression, sur des inhibiteurs de la TNFα-con, sur des inhibiteurs modifiés pour servir de ligands pour la purification de la TNFα-con par affinité, et sur des procédés de traitement de maladies ou d'états pathologiques dus à des taux anormaux de TNFα chez des mammifères.
PCT/EP1997/001497 1996-03-26 1997-03-25 Convertase du facteur alpha de necrose tumorale WO1997035538A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU22913/97A AU2291397A (en) 1996-03-26 1997-03-25 Tumor necrosis factor alpha convertase
EP97915426A EP0900272A2 (fr) 1996-03-26 1997-03-25 Convertase du facteur alpha de necrose tumorale
JP9534033A JP2000507943A (ja) 1996-03-26 1997-03-25 腫瘍壊死因子αコンバーターゼ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62066396A 1996-03-26 1996-03-26
US08/620,663 1996-03-26

Publications (2)

Publication Number Publication Date
WO1997035538A2 WO1997035538A2 (fr) 1997-10-02
WO1997035538A3 true WO1997035538A3 (fr) 1997-11-20

Family

ID=24486845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001497 WO1997035538A2 (fr) 1996-03-26 1997-03-25 Convertase du facteur alpha de necrose tumorale

Country Status (5)

Country Link
EP (1) EP0900272A2 (fr)
JP (1) JP2000507943A (fr)
AU (1) AU2291397A (fr)
CA (1) CA2249985A1 (fr)
WO (1) WO1997035538A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180403B1 (en) * 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US5830742A (en) * 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
WO1996041624A1 (fr) * 1995-06-08 1996-12-27 Immunex Corporation Enzyme de conversion du facteur de necrose tumorale alpha
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
DE69936445T2 (de) * 1998-02-04 2008-04-10 Immunex Corp., Seattle Kristallines tnf-alpha-konvertierendes enzym und verwendung davon
US6632667B1 (en) * 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
US6458552B1 (en) 2000-06-06 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Metalloprotease peptide substrates and methods
WO2002006227A1 (fr) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de la metalloprotease matricielle
US7888324B2 (en) 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
WO2005080560A1 (fr) * 2004-02-05 2005-09-01 Warner-Lambert Company Llc Domaine catalytique de tace mutante
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
WO2007131237A2 (fr) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Composés et procédés permettant de moduler l'expression de la protéine ptp1b
WO2007138236A1 (fr) * 2006-05-24 2007-12-06 The University Of Birmingham Enzymes de type sheddase pour la croissance des neurones
BRPI0809320A2 (pt) 2007-03-24 2014-09-23 Genzyme Corp Método
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
WO2010107838A1 (fr) 2009-03-16 2010-09-23 Isis Pharmaceuticals, Inc. Ciblage de l'apolipoprotéine b pour la réduction de l'apolipoprotéine c-iii

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000378A1 (fr) * 1990-06-22 1992-01-09 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Sequence d'adn pour une protease de serine et objets s'y rapportant
WO1995024501A1 (fr) * 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions pour l'inhibition de la formation des facteurs de necrose tumorale (tnf) et leur utilisation
WO1996041624A1 (fr) * 1995-06-08 1996-12-27 Immunex Corporation Enzyme de conversion du facteur de necrose tumorale alpha

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000378A1 (fr) * 1990-06-22 1992-01-09 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Sequence d'adn pour une protease de serine et objets s'y rapportant
WO1995024501A1 (fr) * 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions pour l'inhibition de la formation des facteurs de necrose tumorale (tnf) et leur utilisation
WO1996041624A1 (fr) * 1995-06-08 1996-12-27 Immunex Corporation Enzyme de conversion du facteur de necrose tumorale alpha

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 97, Philadelphia, PA, US; abstract no. 400580, WENNOGLE L P ET AL: "Stabilization of C5a receptor-G-protein interactions through ligand binding." XP002034338 *
BLACK R A ET AL: "A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.", NATURE (LONDON) 385 (6618). 1997. 729-733. ISSN: 0028-0836, XP002034337 *
DE BOER A H ET AL: "Affinity purification of GTPase proteins from oat root plasma membranes using biotinylated GTP.", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS 337 (3). 1994. 281-284. ISSN: 0014-5793, XP002034334 *
JOURNAL OF CELLULAR BIOCHEMISTRY 55 (3). 1994. 380-388. ISSN: 0730-2312 *
M. WILCHECK ET AL: "Affinity chromatography", METHODS IN ENZYMOLOGY, vol. 104, 1984, pages 3 - 55, XP002034333 *
MCGEEHAN G M ET AL: "REGULATION OF TUMOUR NECROSIS FACTOR-ALPHA PROCESSING BY A METALLOPROTEINASE INHIBITOR", NATURE, vol. 370, no. 6490, 18 August 1994 (1994-08-18), pages 558 - 561, XP000574095 *
MOHLER K M ET AL: "PROTECTION AGAINST A LETHAL DOSE OF ENDOTOXIN BY AN INHIBITOR OF TUMOUR NECROSIS FACTOR PROCESSING", NATURE, vol. 370, no. 6486, 21 July 1994 (1994-07-21), pages 218 - 220, XP000574714 *
MOSS M L ET AL: "Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.", NATURE (LONDON) 385 (6618). 1997. 733-736. ISSN: 0028-0836, XP002034336 *

Also Published As

Publication number Publication date
JP2000507943A (ja) 2000-06-27
WO1997035538A2 (fr) 1997-10-02
EP0900272A2 (fr) 1999-03-10
CA2249985A1 (fr) 1997-10-02
AU2291397A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
WO1997035538A3 (fr) Convertase du facteur alpha de necrose tumorale
CA2400295A1 (fr) Facteur viii modifie
CA2249233A1 (fr) Codage des apotose proteases mch4 et mch5 par des acides nucleiques, et methodes d'utilisation
IL193366A0 (en) Fibroblast growth factor -19
ATE195140T1 (de) Peniophora phytase
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
ATE384798T1 (de) Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren
IL193886A (en) Antibodies that bind to ldcam sequences
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
SI0917571T1 (en) Agouti-related gene
AU3802595A (en) Tripeptidyl aminopeptidase
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
EP0828003A3 (fr) Sérine protéase humaine
Hayashi et al. Purification and characterization of arylamidase from monkey brain
CA2252493A1 (fr) Gene de la .beta.-galactoside - .alpha. 2,6-sialyltransferase
WO1998040498A3 (fr) Immunoadhesines et procedes de production et d'utilisation de ces dernieres
WO1998011234A3 (fr) Proteines kinases humaines
CA2198828A1 (fr) Methode pour accroitre la thermostabilite des enzymes cellulasiques par elimination des domaines de fixation de la cellulose
NZ334259A (en) Fibroblast growth factor homologous factor (FHFs) peptides and nucleic acids that encode them and therapeutic and diagnostic methods for cell proliferative disorders
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
AP9901461A0 (en) Purified proteins, recombinant DNA sequences and process for controlling the ripening of coffee plants.
WO2002010399A1 (fr) Nouvelle carbonyl reductase, son gene et son procede d'utilisation
JP5080787B2 (ja) タンパク質改変方法、ニトリルヒドラターゼ成熟化方法、成熟化ニトリルヒドラターゼ生産方法、成熟化ニトリルヒドラターゼを用いたアミド化合物生産方法
JP2000262292A5 (fr)
EP0303997B1 (fr) Hydrolase de peptides acylés, méthodes de fabrication et utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2249985

Country of ref document: CA

Ref country code: CA

Ref document number: 2249985

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997915426

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997915426

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997915426

Country of ref document: EP